Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review.

Litao Zhang, Lin Kang, Jing Ai, Jing Zhao, Shuang Zhang, Yimeng Qian

Journal: Cancer biotherapy & radiopharmaceuticals 2024;39(4):318-321

PMID: 38324046

Abstract

Malignant glomus tumors (MGTs) are rare malignancies, which grow rapidly and are aggressive. Surgical resection has been regarded as the standard management, but treatment options for those unresectable tumors are limited, resulting in a high recurrence rate and poor prognosis. An 85-year-old man presented with gross hematuria and was diagnosed with MGTs of bladder. The patient achieved long-term local control after multimodal therapy comprising radiotherapy, iodine-125 seeds brachytherapy, transcatheter arterial chemoembolization, and antiangiogenic targeted therapy. MGTs occurring in the bladder are clinically rare and refractory. The case presented here highlights the importance of multidisciplinary diagnosis and treatment, providing evidence that radiotherapy and antiangiogenic therapy may play an important role in unresectable bladder MGT.

Address: Department of Oncology, Hebei General Hospital, Shijiazhuang, China.; Graduate School, North China University of Science and Technology, Tangshan, China.; Department of Oncology, Hebei General Hospital, Shijiazhuang, China.; Graduate School, Hebei North University, Zhangjiakou, China.; Department of Pathology, and Hebei General Hospital, Shijiazhuang, China.; Department of Emergency, Hebei General Hospital, Shijiazhuang, China.; Department of Oncology, Hebei General Hospital, Shijiazhuang, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.